DUBLIN, Ireland, December 3, 2020 — Critical Path Institute, Ltd. (C-Path, Ltd.) announced today a new contract with the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU). The new project will leverage C-Path’s global expertise in developing novel product development tools.Continue reading
Governor Ducey Announces Latest Actions To Fight COVID-19, Increase Hospital StaffingContinue reading
Have you dreamed of starting your own business? Are you obsessed with the idea of making the world a better place? Are you impatient for progress? Do you have a great idea, but don’t know where to start?Continue reading
TUCSON, Ariz., December 2, 2020 — The Critical Path Institute (C-Path) today announced it has been awarded a U.S. Food and Drug Administration (FDA) contract in support of the development of open-source tools to improve the efficiency of trial design for three neuroscience diseases: Alzheimer’s disease (AD), Parkinson’s disease (PD) and Duchenne muscular dystrophy (DMD). C-Path’s Quantitative Medicine (QuantMed) Program will carry out the project through its work in collaboration with its three C-Path Public-Private Partnerships: the Critical Path for Alzheimer’s Disease (CPAD), the Critical Path for Parkinson’s (CPP) and the Duchenne Regulatory Science Consortium (D-RSC).Continue reading
Check out these opportunities to participate in #Giving Tuesday and to support AZBio Members and AZBio Community Programs
Award will fund a collaborative effort between AquaVitas, LLC, the Centers for Disease Control and Prevention and Health and Human Services to identify best practices for wastewater SARS- CoV-2 assessment and subsequent data analytics across the U.S.
Phase 1 award will fund assessment of wastewater at up to 100 treatment plants (representing ~10% of the U.S. population).
Optional Phase 2 award will scale to fund assessment of wastewater at up to 340 treatment plants (representing ~30% of the U.S. population in at least 42 states).Continue reading
TEMPE, Ariz.–(BUSINESS WIRE)–Calviri, Inc. (www.calviri.com) announces today the appointment of Michael McCallister to the company’s Board of Directors. Mr. McCallister has a breadth of governance and management experience in multiple industries, including health insurance, financial services, and animal life sciences.Continue reading
GammaTile Therapy Offers Patients a Proven Option to Slow Brain Tumor Progression, Delay Recurrence and Avoid Additional Trips to the Hospital for Radiation TherapyContinue reading
First treatment of any kind to have prospectively confirmed and statistically significant anti-viral activity against SARS-CoV-2
Authorized for recently diagnosed, mild to moderate COVID-19 in high-risk patients
Initial doses of REGEN-COV2 will be made available to approximately 300,000 patients, with no medication out-of-pocket costs, under U.S. government allocation programContinue reading